EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Balloon-in-Basket Pulsed Field Ablation for Pulmonary Vein Isolation

Atul Verma, Monica Lo, Christopher E Woods, Ayman A Hussein, Alok Gambhir, Sri Sundaram, Prashanthan Sanders, David DeLurgio, Stavros E Mountantonakis, Petr Neuzil, Joaquin Osca, Amar Trivedi und 14 weitere

JACC: Clinical Electrophysiology · 2026-06 · 12 (6) · 1287-1299

DOI: 10.1016/j.jacep.2026.01.006 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Clinical Electrophysiology, 2026-06. Verfasst von Atul Verma und 25 weiteren Autor:innen. Beteiligte Einrichtung: McGill University Health Centre, Montreal, Quebec, Canada. Electronic address: atul.verma@mcgill.ca. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Irreversible Electroporation Therapy, Pulmonary Veins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Abbott Vascular Devices.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: A novel balloon-in-basket catheter integrated into a mapping system may advance pulsed field ablation (PFA) of atrial fibrillation (AF) with demonstrated deeper lesions, less hemolysis, and promising initial clinical experience. OBJECTIVES: The goal of this study was to assess the 1-year clinical outcomes of the balloon-in-basket PFA system. METHODS: The multicenter VOLT-AF IDE Clinical Study enrolled patients with symptomatic, paroxysmal (PAF), and persistent AF (PeAF) . Pulmonary vein isolation (PVI) was performed with the investigational system. The primary effectiveness endpoint was acute PVI and 12-month freedom from atrial arrhythmia, antiarrhythmic escalation/initiation, cardioversion, or repeat ablation. The primary safety endpoint was device- and/or procedure-related serious adverse events within 7 days of any ablation. Follow-up consisted of 12-lead electrocardiograms at discharge, 3 months, and 12 months; biweekly and symptomatic transtelephonic monitoring; and 24-hour Holter monitoring at 12 months. RESULTS: Of the 392 patients enrolled, 335 were main cohort patients (57 roll-ins), and 320 were treated (165 PAF and 155 PeAF). Their mean age was 65 ± 11 years, and the mean CHA2DS2-VASc score was 2.3 ± 1.6. Left atrial catheter dwell time was 44.1 ± 18.1 minutes (including a 20-minute wait). A mean of 4.6 ± 0.9 applications were delivered per vein. Primary effectiveness was 81.1% (95% CI: 74.3%-86.3%) in PAF and 63.3% (95% CI: 55.1%-70.4%) in PeAF. Freedom from documented arrhythmia recurrence was 84.2% in the PAF group and 67.8% in the PeAF group. Primary safety events occurred in 1.9% of patients, with none in the PAF group. During redo ablation in 19 patients, 78.5% of pulmonary veins remained durably isolated. CONCLUSIONS: This multicenter trial reports high PVI-based effectiveness of the novel balloon-in-basket PFA device with excellent safety.(VOLT-AF IDE Clinical Study; NCT06223789).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationIrreversible Electroporation TherapyPulmonary VeinsAgedFemaleHumansMaleMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

ablationatrial fibrillationballoonclinical trialdurabilityparoxysmalpersistentpulmonary vein isolationpulsed field ablationspline

Autor:innen und Institutionen

  • McGill University Health Centre, Montreal, Quebec, Canada. Electronic address: atul.verma@mcgill.ca.
  • Arkansas Heart Hospital, Little Rock, Arkansas, USA.
  • Sutter California Pacific Medical Center-Van Ness Campus, San Francisco, California, USA.
  • Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Northside Hospital, Atlanta, Georgia, USA.
  • South Denver Cardiology Associates, Denver, Colorado, USA.

Förderung

  • Abbott Vascular Devices

Zitieren

APA

Verma, A., Lo, M., Woods, C. E., Hussein, A. A., Gambhir, A., Sundaram, S., Sanders, P., DeLurgio, D., Mountantonakis, S. E., Neuzil, P., Osca, J., Trivedi, A., Loh, P., Calkins, H., Strouse, D., Chierchia, G. B., Atwater, B., Kalman, J., Puererfellner, H., …, & Lakkireddy, D. (2026). Balloon-in-Basket Pulsed Field Ablation for Pulmonary Vein Isolation. JACC: Clinical Electrophysiology, 12(6), 1287-1299. https://doi.org/10.1016/j.jacep.2026.01.006

Vancouver

Verma A, Lo M, Woods CE, Hussein AA, Gambhir A, Sundaram S, et al. Balloon-in-Basket Pulsed Field Ablation for Pulmonary Vein Isolation. JACC: Clinical Electrophysiology. 2026;12(6):1287-1299. doi:10.1016/j.jacep.2026.01.006

BibTeX
@article{Verma2026,
  author = {Verma, Atul and Lo, Monica and Woods, Christopher E and Hussein, Ayman A and Gambhir, Alok and Sundaram, Sri and Sanders, Prashanthan and DeLurgio, David and Mountantonakis, Stavros E and Neuzil, Petr and Osca, Joaquin and Trivedi, Amar and Loh, Peter and Calkins, Hugh and Strouse, David and Chierchia, Gian-Battista and Atwater, Brett and Kalman, Jonathan and Puererfellner, Helmut and Russo, Antonio Dello and Davoudi, Ramin and Schilling, Richard and Lin, Wenjiao and Miller, Amber and Jesser, Emily and Lakkireddy, Dhanunjaya},
  title = {Balloon-in-Basket Pulsed Field Ablation for Pulmonary Vein Isolation},
  journal = {JACC: Clinical Electrophysiology},
  year = {2026},
  volume = {12},
  number = {6},
  pages = {1287--1299},
  doi = {10.1016/j.jacep.2026.01.006}
}
Kostenlos starten →